Login
← Go Back
Divi's Laboratories
DIVISLAB · Pharma > Pharmaceuticals & Drugs · Chairman: Ramesh BV Nimmagadda · MD: Murali K Divi · Listing date: March 12, 2003 · Employees: 16818 · Hyderabad · http://www.divislabs.com
Stock Price vs Company Growth
1d
2.6%
1w
2.8%
1m
4.0%
3m
6.1%
6m
32.6%
1y
47.6%
5y
27.0%
10y
22.7%
all
23.5%
🤔 How to analyze this graph?
Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price
₹ 5,887 2.6%
5,635
6,449
Company Overview
Sales
8,614 Cr
Growth: 7.0%
Profit after Tax
1,836 Cr
Growth: 9.7%
Large Cap
1,56,280 Cr
P/E: 85.1x
Industry P/E: 38.0x
Fundamentals
Sales (Cr) ₹ 8,614
Growth 7.0%
EBITDA 29.7%
P/S 18.1x
Dividend 0.8%
P/E 85.1x
Book Value ₹ 547
PEG Ratio 12.2x
ROE 13.1%
P/B 10.8x
Shareholding Pattern
Institutions
Sbi Mutual Fund
4.49 %
Qualified Institutional Buyer
3.57 %
Axis Mutual Fund Trustee Ltd
3.37 %
Government Pension Fund Global
1.29 %
Life Insurance Corporation Of India
1.15 %
Promoters
Nilima Prasad Divi
20.34 %
Divi Satchandra Kiran
20.34 %
Divi Swarna Latha
5.27 %
Divi'S Biotech Private Limited
3.01 %
Murali Krishna Prasad Divi
2.85 %
Others
Increase    Decrease    No change
Company Profile Detailed
The Company manufactures Generic APIs, Nutraceutical Ingredients and offers Custom Synthesis of APIs to Big Pharma providing a competitive advantage over the entire life cycle of the products.
Belongs to (39 Indices) view more
Investors (130)
divi.mad...
g.v.rao
dr.mural...
Followers (41)
deepak
jayapras...
nitin2